Brief: Adaptimmune Reports Positive Data With LETE-CEL(1) From An Interim Analysis Of Pivotal IGNYTE-ESO Trial For People With Synovial Sarcoma Or MRCLS

Adaptimmune Therapeutics

31/10/2023 12:15

Oct 31 (Reuters) - Adaptimmune Therapeutics PLC
 ADAP.O :
    * ADAPTIMMUNE REPORTS POSITIVE DATA WITH LETE-CEL(1) FROM AN
INTERIM ANALYSIS OF PIVOTAL IGNYTE-ESO TRIAL FOR PEOPLE WITH
SYNOVIAL SARCOMA OR MRCLS
    * ADAPTIMMUNE THERAPEUTICS: OVERALL SAFETY PROFILE OF
LETE-CEL WAS
ACCEPTABLE, INCLUDING CRS AND REVERSIBLE HEMATOLOGIC TOXICITIES

Further company coverage:  ADAP.O